Camp4 Therapeutics Corp (NASDAQ: CAMP)

Sector: Healthcare Industry: Biotechnology CIK: 0001736730
P/B 3.04
P/E -3.34
P/S 46.86
Market Cap 178.17 Mn
ROIC (Qtr) -95.91
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 6.35 Mn
Debt/Equity (Qtr) 0.11

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 76.88M provide 23.63x coverage of short-term debt 3.25M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 86.39M provides 13.61x coverage of total debt 6.35M, indicating robust asset backing and low credit risk.
  • Tangible assets of 86.39M provide robust 21.25x coverage of other current liabilities 4.07M, indicating strong asset backing.
  • Strong cash position of 76.88M provides 18.91x coverage of other current liabilities 4.07M, indicating excellent liquidity.
  • Cash reserves of 76.88M provide robust 9.73x coverage of current liabilities 7.90M, indicating strong short-term solvency.

Cons

  • Investment activities of (506000) provide weak support for R&D spending of 39.84M, which is -0.01x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (47.13M) shows concerning coverage of stock compensation expenses of 3.64M, with a -12.93 ratio indicating potential earnings quality issues.
  • Free cash flow of (47.64M) provides weak coverage of capital expenditures of 506000, with a -94.15 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (53.40M) show weak coverage of depreciation charges of 3.59M, with a -14.87 ratio indicating high capital intensity and potential reinvestment needs.
  • Operating cash flow of (47.13M) barely covers operating expenses of 494000 with a -95.41 ratio, suggesting thin operational efficiency margins and limited flexibility.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 1.68 12.31
EV to Cash from Ops. -3.07 23.25
EV to Debt 22.80 738.44
EV to EBIT -2.71 -9.16
EV to EBITDA -2.88 6.95
EV to Free Cash Flow [EV/FCF] -3.04 21.90
EV to Market Cap 0.81 65.67
EV to Revenue 38.06 227.32
Price to Book Value [P/B] 3.04 22.34
Price to Earnings [P/E] -3.34 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % -20.19 -27.13
Cash and Equivalents Growth (1y) % 1,751.61 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -3.68 -46.93
EBITDA Growth (1y) % -2.26 -1.68
EBIT Growth (1y) % -3.68 -56.45
EBT Growth (1y) % -3.68 -12.70
EPS Growth (1y) % 159.54 -28.31
FCF Growth (1y) % -2.50 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.04 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 9.73 3.85
Current Ratio 9.83 7.27
Debt to Equity Ratio 0.11 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % -1,310.00 -18,234.31
EBIT Margin % -1,404.47 -18,580.80
EBT Margin % -1,404.47 -19,488.74
Gross Margin % 100.00 -7.59
Net Profit Margin % -1,404.50 -19,439.22